Sanofi Q4 EPS Beats Estimates; €1.53 EPS Up 26.7%, 2026 Growth Outlook
Sanofi reported fourth-quarter adjusted earnings of $0.89 per American depositary share, beating the Zacks estimate of $0.84. Reported EPS of €1.53 per share rose 16.8% on a reported basis and 26.7% on a constant currency basis, driven by cost-control measures, as the company expects profitable growth in 2026.
1. Sanofi Reports Strong Q4 Earnings and Positive Growth Outlook
Sanofi reported fourth-quarter 2025 adjusted earnings of $0.89 per American Depositary Share, surpassing the consensus estimate of $0.84. On a reported basis, earnings per share rose 16.8% to €1.53, while on a constant currency basis they climbed 26.7%, driven primarily by rigorous cost-control measures and efficiency initiatives across global operations. The company highlighted ongoing margin improvement in its key Specialty Care and Vaccines franchises, which together contributed over 60% of total revenue for the quarter. Looking ahead, Sanofi reiterated its commitment to profitable growth in 2026, targeting mid-single-digit net sales growth and further margin expansion through disciplined expense management and strategic investment in pipeline programs.